US 12,409,233 B2
Anti-PD-L1 single-domain antibody and derivatives and use thereof
Yifeng Xu, Guangdong (CN); Tianhang Zhai, Guangdong (CN); Zhijun Yuan, Guangdong (CN); Andy Tsun, Guangdong (CN); Tsoyue Joanne Sun, Guangdong (CN); and Weifeng Huang, Guangdong (CN)
Assigned to BIOTHEUS INC., Guangdong (CN)
Appl. No. 17/642,171
Filed by BIOTHEUS INC., Guangdong (CN)
PCT Filed Sep. 7, 2020, PCT No. PCT/IB2020/058303
§ 371(c)(1), (2) Date Mar. 10, 2022,
PCT Pub. No. WO2021/048725, PCT Pub. Date Mar. 18, 2021.
Claims priority of application No. 201910863109.0 (CN), filed on Sep. 12, 2019.
Prior Publication US 2022/0315658 A1, Oct. 6, 2022
Int. Cl. C07K 14/71 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC A61K 47/6849 (2017.08) [A61P 35/00 (2018.01); C07K 14/71 (2013.01); C07K 16/2827 (2013.01); A61K 2039/505 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/30 (2013.01)] 10 Claims
 
1. An anti-PD-L1 single-domain antibody comprising a complementarity determining region (CDR), wherein the CDR of the VHH chain consists of the following:
CDR1 with an amino acid sequence as shown in SEQ ID NO: 1;
CDR2 with an amino acid sequence as shown in SEQ ID NO: 93, 81, 84, 87, 90, 96, 2 or 7; and
CDR3 with an amino acid sequence as shown in SEQ ID NO: 3.